Gallop Oncology
LYT-200
relapsed/refractory high-risk myelodysplastic syndrome
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on LYT-200 for relapsed/refractory high-risk myelodysplastic syndrome is expected Date TBD.
Primary source
· SEC 6-K
verified 12h ago
“January 2025: FDA granted Fast Track Designation to LYT-200 for the treatment of AML, which is intended to streamline the development and accelerate the assessment of drugs that target serious conditions with unmet medical need.”